S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Sell every Stock except ONE (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
The "King Of Quants" sees 10X potential... (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
The "King Of Quants" sees 10X potential... (Ad)
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Sell every Stock except ONE (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
The "King Of Quants" sees 10X potential... (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
The "King Of Quants" sees 10X potential... (Ad)
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Sell every Stock except ONE (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
The "King Of Quants" sees 10X potential... (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
The "King Of Quants" sees 10X potential... (Ad)
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Sell every Stock except ONE (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
The "King Of Quants" sees 10X potential... (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
The "King Of Quants" sees 10X potential... (Ad)
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
NYSE:PEN

Penumbra - PEN Stock Forecast, Price & News

$278.69
+1.60 (+0.58%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$278.40
$282.68
50-Day Range
$238.86
$278.69
52-Week Range
$114.86
$283.42
Volume
369,110 shs
Average Volume
327,710 shs
Market Capitalization
$10.64 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$265.42

Penumbra MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
4.8% Downside
$265.42 Price Target
Short Interest
Bearish
11.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.25
Upright™ Environmental Score
News Sentiment
0.36mentions of Penumbra in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$7.27 M Sold Last Quarter
Proj. Earnings Growth
86.40%
From $1.25 to $2.33 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

494th out of 996 stocks

Surgical & Medical Instruments Industry

48th out of 104 stocks


PEN stock logo

About Penumbra (NYSE:PEN) Stock

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.

Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Stock News Headlines

Are These Medical Device Makers Getting Ready To Rally? (PEN)
Current trends and changing demographics are behind growth of medical technology companies. An aging population and a shift to in-home care are among factors.
Penumbra (NYSE:PEN) Downgraded by Needham & Company LLC
This Tech Stock Could be the Next Amazon
You can learn its name in Luke Lango’s latest report, 5 Hypergrowth Stocks for 2023. Claim Your Free Report Here. pixel
Q4 2022 Penumbra Inc Earnings Call
5 Hypergrowth Stocks to Buy Now
Luke Lango has found 14 stocks that have gone up over 1,000%. Now he’s named his top stocks for 2023. Just click to claim your copy. pixel
Penumbra (PEN) Q4 Earnings and Revenues Surpass Estimates
Should You Buy Penumbra (PEN) Ahead of Earnings?
Penumbra (PEN) Tops Q3 Earnings and Revenue Estimates
See More Headlines
Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Company Calendar

Last Earnings
2/23/2023
Today
4/01/2023
Next Earnings (Estimated)
5/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Employees
3,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$265.42
High Stock Price Forecast
$303.00
Low Stock Price Forecast
$185.00
Forecasted Upside/Downside
-4.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
13 Analysts

Profitability

Net Income
$-2,000,000.00
Pretax Margin
0.46%

Debt

Sales & Book Value

Annual Sales
$847.13 million
Cash Flow
$0.82 per share
Book Value
$26.30 per share

Miscellaneous

Free Float
36,079,000
Market Cap
$10.64 billion
Optionable
Optionable
Beta
0.52

Key Executives

  • Adam ElsesserAdam Elsesser
    Chairman, President & Chief Executive Officer
  • Ben Sorci
    Executive Vice President-Operations
  • Maggie S. Yuen
    Chief Financial Officer
  • Pankaj Tiwari
    Chief Information Officer & Executive VP
  • Corey L. Teigen
    Chief Scientific Officer













PEN Stock - Frequently Asked Questions

Should I buy or sell Penumbra stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last twelve months. There are currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PEN shares.
View PEN analyst ratings
or view top-rated stocks.

What is Penumbra's stock price forecast for 2023?

13 brokers have issued 1 year price targets for Penumbra's stock. Their PEN share price forecasts range from $185.00 to $303.00. On average, they predict the company's share price to reach $265.42 in the next year. This suggests that the stock has a possible downside of 4.8%.
View analysts price targets for PEN
or view top-rated stocks among Wall Street analysts.

How have PEN shares performed in 2023?

Penumbra's stock was trading at $222.46 at the beginning of the year. Since then, PEN stock has increased by 25.3% and is now trading at $278.69.
View the best growth stocks for 2023 here
.

When is Penumbra's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our PEN earnings forecast
.

How were Penumbra's earnings last quarter?

Penumbra, Inc. (NYSE:PEN) released its quarterly earnings data on Thursday, February, 23rd. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.14 by $0.02. The firm earned $221.22 million during the quarter, compared to the consensus estimate of $217.03 million. Penumbra had a positive trailing twelve-month return on equity of 0.66% and a negative net margin of 0.24%. Penumbra's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.10 earnings per share.

What guidance has Penumbra issued on next quarter's earnings?

Penumbra issued an update on its FY 2023 earnings guidance on Thursday, February, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.00B-, compared to the consensus revenue estimate of $1.00 billion.

What is Adam Elsesser's approval rating as Penumbra's CEO?

57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), Boeing (BA) and DexCom (DXCM).

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

How do I buy shares of Penumbra?

Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $278.69.

How much money does Penumbra make?

Penumbra (NYSE:PEN) has a market capitalization of $10.64 billion and generates $847.13 million in revenue each year. The company earns $-2,000,000.00 in net income (profit) each year or ($0.06) on an earnings per share basis.

How many employees does Penumbra have?

The company employs 3,900 workers across the globe.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The official website for the company is www.penumbrainc.com. The company can be reached via phone at (510) 748-3200, via email at investors@penumbrainc.com, or via fax at 510-748-3232.

This page (NYSE:PEN) was last updated on 4/2/2023 by MarketBeat.com Staff